MedPath

Scale Validation Study for Prediction of Relapse and Short Term Rehospitalization in Patients With Schizophrenia

Completed
Conditions
Schizophrenia
Interventions
Other: No intervention
Registration Number
NCT00358852
Lead Sponsor
Janssen-Cilag, S.A.
Brief Summary

The purpose of this study is to establish and validate a scale/model that can be used to evaluate the duration of time and factors between short term hospital treatment and subsequent relapse periods in patients with schizoaffective/schizophreniform disorders.

Detailed Description

This is an epidemiological (study of the distribution and determinants of health-related states or events in defined population), multicenter (study conducted at multiple sites), observational (study in which patients are observed), cross-sectional (observation of all patients at one specific point in time), prospective (in which the patients are first identified and then followed forward as time passes) study. The sources of information in the study are units medical short stay psychiatric hospitalization or the acute care of the whole country, and clinical data of the patient at discharge. No intervention will be provided in this study. The general data (age range, gender, highest level of educational attainment, level of family support, substance abuse, events stressors, type of schizophrenia according to DSM-IV criteria \[Diagnostic and Statistical Manual fourth\], etc) of approximately 2000 schizophrenia and schizoaffective disorder / schizophreniform patients will be collected in this study. No special tests will be done during the study. The study will collect patients' data in electronic data collection workbook and model validation will be used at 6 and 12 months to confirm no relapse / hospitalization. The study observation period corresponds to the 3 years preceding the current relapse and current income (current hospitalization period) and 12 months after admission.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
2339
Inclusion Criteria
  • Patients with Schizophrenia or Schizoaffective disorder of more than 2 years evolution and who find themselves admitted in a Short-Term Psychiatric Hospitalization Unit or Acute Unit
Exclusion Criteria
  • Other patients with a psychiatric pathology different to schizophrenia, schizoaffective/schizophreniform disorders
  • Patients with schizophrenia or schizoaffective/schizophreniform disorders of 2 years, or less evolution
  • Pregnant, lactating, or planning to become pregnant within the next 12 months

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Patients with SchizophreniaNo intervention-
Primary Outcome Measures
NameTimeMethod
Number of readmission of patientsUp to 12 months

Readmission in short-stay psychiatric hospital units when the schizophrenia or schizoaffective or schizophreniform disorder relapse.

Time to short-term relapseUp to 12 months

Time to early relapse of patients discharged from a short-stay psychiatric hospitalisation unit.

Clinical Global Impression - Severity (CGI-S) ScoreUp to 3 years

The CGI-S rating scale is used to rate the severity of a patient's psychotic condition on a 7-point scale. It is rated as follows: 1=Normal, not at all ill, 2=Borderline mentally ill, 3=Mildly ill, 4=Moderately ill, 5=Markedly ill, 6=Severely ill, and 7=Among the most extremely ill. Higher scores indicate worsening.

Secondary Outcome Measures
NameTimeMethod
Drug abuseWithin 3 years before the study start
Previous stress or eventWithin 3 years before the study start
Hospitalizations in the previous 3 yearsWithin 3 years before the study start
Adherence to the psychiatric treatmentWithin 3 years before the study start
Previous pharmacological treatmentWithin 3 years before the study start
Duration of diseaseWithin 3 years before the study start
Psychiatric diagnosisWithin 3 years before the study start

Patients diagnosed with Schizophrenia or Schizoaffective/schizophreniform disorder.

© Copyright 2025. All Rights Reserved by MedPath